You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 12 Next »




Project Scope
Development and delivery of education relevant to clinical trial safety analyses, with a focus on Phase 2-3.

Problem Statement 

Problem Impact 

Project Leads

Emails

Christopher Smith, FDA

Christopher.Smith2@fda.hhs.gov

William Palo, AbbVie

william.palo@abbvie.com

Nicola Newton, PHUSE Project Assistant

nicky@phuse.global

CURRENT STATUS Q1 2024

  • Calling for Volunteers 

Safety Analytics Webinar Series 2023: 

Date      

Title  

Speakers

Recording

15 June

Scientific Evaluation of Safety Data and Aggregate Safety Assessment Planning for IND Safety ReportingGreg Ball, ASAP Process Consulting, Jacqueline Corrigan-Curay, FDA, Barbara Hendrickson, University of Chicago & Brian Waterhouse, MerckRecording
13 JulyOverall Safety Assessment – Standard Safety Tables and FiguresJim Buchanan, Covilance), Mary Nilsson, Eli Lilly & Veronica Pei, FDARecording
14 September     

Overall Safety Assessment – AE Groupings for Assessment of Safety Topics of Interest

Greg Ball, ASAP Process Consulting, Mac Gordon, Johnson & Johnson), Peg Fletcher, MedAssessment & Scott Proestel, FDA

Recording 
4 October

Overall Safety Assessment – Interactive Safety Graphics for Regulatory Decision-Making

Jeremy Wildfire, Gilead, Steve Mallett, Veramed & Mat Soukup, FDA/CDER

Recording
16 November

Interdisciplinary Safety Evaluation for Learning and Decision-Making: Education for Executives              

Greg Ball, ASAP Process Consulting, Jacqueline Corrigan-Curay, FDA, Barbara Hendrickson, University of Chicago & Sheila Mahoney-Jewels, LifeSciHub 

Recording
  • No labels